Progress of KRAS G12C mutations in non-small cell lung cancer
10.3760/cma.j.cn371439-20231008-00013
- VernacularTitle:非小细胞肺癌KRAS G12C突变的研究进展
- Author:
Zhenghong MA
1
;
Chao JIANG
Author Information
1. 山东第一医科大学第三附属医院放疗科，济南 250031
- Keywords:
KRAS;
Carcinoma, non-small-cell lung;
Molecular targeted therapies
- From:
Journal of International Oncology
2024;51(2):95-98
- CountryChina
- Language:Chinese
-
Abstract:
With the continuous in-depth research on the mechanism of KRAS G12C mutations in targeted therapy of non-small cell lung cancer, KRAS G12C has evolved from non producible to an important targeted therapy site. The KRAS G12C mutation inhibitor has achieved dual progress in efficiency and survival in targeted therapy of non-small cell lung cancer. Although drug resistance is inevitable with treatment, research on drug resistance mechanisms has found that combination medication is one of the ways to overcome or reduce drug resistance.
